Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.68 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11355392 | 1.00 | ANPEP (0.68) | ANPEPPLAUIDO1SLC18A3HTR2A | |
| SCHEMBL11355395 | 1.00 | ANPEP (0.68) | ANPEPPLAUIDO1SLC18A3HTR2A | |
| SCHEMBL9515304 | 1.00 | ANPEP (0.68) | ANPEPPLAUIDO1SLC18A3HTR2A | |
| SCHEMBL3996873 | 1.00 | ANPEP (0.68) | ANPEPPLAUIDO1SLC18A3HTR2A | |
| SCHEMBL30070669 | 1.00 | ANPEP (0.68) | ANPEPPLAUIDO1SLC18A3HTR2A | |
| SCHEMBL10067966 | 0.83 | ANPEP (0.96) | ANPEPPLAUSLC18A3 | |
| SCHEMBL4024386 | 0.82 | PLAU (0.54) | ANPEPPLAUIDO1HTR2A | |
| SCHEMBL20063792 | 0.82 | ANPEP (0.56) | ANPEPPLAUIDO1SLC18A3 | |
| SCHEMBL6155975 | 0.82 | PLAU (0.54) | ANPEPPLAUIDO1HTR2A | |
| SCHEMBL1990443 | 0.82 | ANPEP (0.56) | ANPEPPLAUIDO1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| WO-2022187491-A1 | INHIBITORS OF CYSTEINE PROTEASES | THE TEXAS A& M UNIVERSITY SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| US-7365061-B2 | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365061-B2 | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-0378456-B1 | TETRALIN DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-09-15 | — | — | EP | disclosed |
| US-5106861-A | Method of using certain tetralin derivatives to produce analgesic relief | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-21 | — | — | US | disclosed |
| US-5041673-A | Aminopeptidase inhibitors, immunomodulators, analgesics | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0381902-A1 | Tetralin derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-16 | — | — | EP | disclosed |
| EP-0378456-A1 | Tetralin derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-07-18 | — | — | EP | disclosed |
| US-4267373-A | HYDROXY- OR -OXY-SUBSTITUTED-6-ALKYL- OR DIALKYLAMINO-7-HYDROXY DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1981-05-12 | — | — | US | disclosed |
| US-4076843-A | 5,6,7,8-Tetrahydronaphthalene hypotensive agents | E. R. SQUIBB & SONS, INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150396-A1 | INHIBITORS OF CYSTEINE PROTEASES | CTRL, SERPINB1, PRSS1 | ANPEP 56/4885PLAU 144/4885IDO1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.